Welcome to the e-CCO Library Archive!
Faecal calprotectin is superior to faecal lactoferrin and S100A12
E.K. Wright1, P.P. De Cruz1, M.A. Kamm1, A.L. Hamilton1, K.J. Ritchie1, E.O. Krejany1, S.T. Leach2, J.I. Keenan2, A. Gorelik1, D. Liew1, L. Prideaux1, I.C. Lawrance1, J.M. Andrews1, P.A. Bampton1, M.P. Sparrow1, T.H. Florin1, P.R. Gibson1, H.S. Debinski1, F.A. Macrae1, R.W. Leong1, I.J. Kronborg1, G.L. Radford-Smith1, W.S. Selby1, M.J. Johnson1, R.J. Woods1, P.R. Elliott1, S.J. Bell1, S.J. Brown1, W.R. Connell1, A.S. Day2, R.B. Gearry2, P.V. Desmond1, 1St Vincent's Hospital & University of Melbourne, Gastroenterology, Melbourne, Australia, 2Christchurch Hospital, Gastroenterology, Christchurch, New Zealand
Predictors of disease relapse of patients with Crohn's disease in Deep Remission: Who and when can withdraw thiopurine maintenance therapy?
Y. Qiu, R. Mao, B.-l. Chen, Y. He, Z.-r. Zeng, M.-h. Chen*
First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China
Autoimmune sclerosing cholangitis is associated with small bowel ulceration on capsule enteroscopy
B. Hayee1, M. Samyn2, D. Shawcross3, M. Heneghan3, I. Bjarnason1, 1King's College Hospital NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2King's College Hospital NHS Foundation Trust, Paediatric Hepatology, London, United Kingdom, 3King's College Hospital NHS Foundation Trust, Insitute of Hepatology, London, United Kingdom
The predictive factor for relapse of ulcerative colitis in patients with endoscopic mucosal healing
K. Yamakawa*1, T. Yoshino2, S. Nishimura1, K. Watanabe1, S. Yazumi1
1Kitano hospital, Gastroenterology, Osaka, Japan, 2Graduate School of Medicine, Kyoto University, Gastroenterology and Hepatology, Kyoto, Japan
Psoriasis phenotype in inflammatory bowel disease: a case–control prospective longitudinal study
E. Lolli1, R. Saraceno2, G. Condino1, C. Petruzziello1, M. Ascolani1, S. Onali1, E. Calabrese1, S. Chimenti2, F. Pallone1, L. Biancone1, 1Università di Roma Tor Vergata, Medicina dei sistemi, cattedra di Gastroenterologia, Roma, Italy, 2Dermatology Unit, University of Rome Tor Vergata, Systems Medicine, Rome, Italy
Impaired mucosal permeability underlies ongoing irritable bowel syndrome-like symptoms, in patients with inflammatory bowel disease who have achieved mucosal healing
J. Chang1, 2, 3, 4, M. Ip1, 3, M. Yang1, 3, B. Wong1, 3, M. Arshi4, T. Phan4, R. Leong*1, 2, 3, 4
1Bankstown Lidcombe Hospital, Gastroenterology and Hepatology, Bankstown, Australia, 2Concord Repatriation General Hospital, Gastroenterology and Hepatology, Concord, Australia, 3University of New South Wales, South Western Sydney Clinical School, Faculty of Medicine, Liverpool, Australia, 4The Garvin Institute of Medical Research, Immunology, Sydney, Australia
Low FODMAP diet reduces irritable bowel symptoms and improves quality of life in patients with inflammatory bowel disease in a randomized controlled trial
N. Pedersen1,2, M. Felding3, D. Ankersen4, Z. Vegh5, J. Burisch4, P. Munkholm4, 1Herlev University Hospital, Department of Gastroenterology, Copenhagen, Denmark, 2University, Gastroenterology, Copenhagen, Denmark, 3University of Copenhagen, Clinical Nutrition, Copenhagen, Denmark, 4University of Copenhagen, Gastroenterology, Herlev, Denmark, 5University of Copenhagen, Gastroenterlogy, Herlev, Denmark
Faecal calprotectin measurements by IBD patients themselves at home are feasible and provide reliable Results compared to the standard lab method.
K. Kofod Vinding*1, H. Elsberg1, T. Thorkilgaard1, D. Marker1, N. Pedersen1, K. Carlsen1, J. Burisch1, P. Munkholm2
1Herlev Hospital, Gastrounit, medical section (54R1M), Herlev, Denmark, 2University of Copenhagen, Clinical Medicine, Copenhagen, Denmark
Cognitive-behavioural therapy (CBT) improves inflammatory responsiveness but not mental health short term in IBD patients: A pilot randomised controlled trial
A. Mikocka-Walus1, P. Hughes2, M. Moretta2, A. Pilichiewicz3, H. Long4, D. Hetzel3, P. Bampton5, J. Andrews3, 1University of York, Health Sciences, York, United Kingdom, 2University of Adelaide, Nerve-Gut Research Laboratory, Discipline of Medicine, Adelaide, Australia, 3Royal Adelaide Hospital, University of Adelaide, IBD Service, Dept of Gastroenterology & Hepatology & School of Medicine, Adelaide, Australia, 4University of Adelaide, School of Psychology, Adelaide, Australia, 5Flinders Medical Centre, Gastroenterology and Hepatology, Adelaide, Australia
DOP068 has been converted to a hard copy poster presentation upon author’s request – please refer to p. S237 (P319a)
Tripeptide KdPT ameliorates intestinal inflammation in patients with mild to moderate active ulcerative colitis
T. Kucharzik1, G. Lemmnitz2, C. Abels2, C. Maaser1, 1Lüneburg Hospital, University of Göttingen, Department of General Medicine and Gastroenterology, Lüneburg, Germany, 2Wolff Pharma, Dermatology, Bielefeld, Germany
A retrospective non-interventional European database analysis assessing adherence and persistence of mild to moderate IBD treatments
P. Lakatos*1, L. Peyrin-Biroulet2, P. Irving3, J. Masure4, W. Man A Hing4, N. Sommerford5
1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 2Nancy University Hospital, Université de Lorraine, Gastroenterology and Hepatology, Vandoeuvre-les-Nancy, France, 3Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, 4Ferring Pharmaceuticals, Global Gastroenterology Department, Saint-Prex, Switzerland, 5Sciensus, University of Sussex, Brighton, United Kingdom
The FFA2 antagonist GLPG0974: opportunity to treat neutrophil-driven inflammation
F. Vanhoutte1, F. Namour2, S. Dupont2, W. Haazen3, M. Petkova3, A. Van der Aa1, G. van 't Klooster1, J. Beetens1, 1Galapagos NV, Clinical Development, Mechelen, Belgium, 2Galapagos SASU, Development, Romainville, France, 3SGS Life Science Services, Clinical Pharmacology Unit, Antwerp, Belgium
Perception of the impact of Ulcerative Colitis in the quality of life of patients from Spain - UC-life survey
F. Argüelles1, A. López-Sanromán2, X. Calvet3, O. Rincón4, C. Romero4, D. Carpio*5
1Hospital Universitario Virgen Macarena, Gastroenterology Unit, Sevilla, Spain, 2Hospital Ramón y Cajal, Gastroenterology Unit, Madrid, Spain, 3Corporació Sanitària Universitària Parc Taulí, Digestive Disease Department. Departament de Medicina. Universitat Autònoma de Barcelona. CIBEREHD – Instituto de Salud Carlos III, Sabadell, Spain, 4Merck Sharp & Dohme, Medical Affairs, Madrid, Spain, 5Complexo Hospitalario Universitario , Gastroenterology, Pontevedra, Spain
Inflammatory bowel diseases: a new cardiovascular risk factor?
L. Caillo1, G. Danan1, V. Georgescu2, L. Papineau1, F. Gonzalez1, J.-F. Bourgaux3, F. Guillon4, G.-P. Pageaux1, R. Altwegg1, 1University Hospital of St Eloi, Departement of Hepatology and Gastroenterology, Montpellier, France, 2University Hospital, Department of Medical Information, Montpellier, France, 3University Hospital, Department of Hepatology and Gastroenterology, Nimes, France, 4University Hospital of St Eloi, Department of Digestive Surgery, Montpellier, France
Endoscopic detection of small bowel adenocarcinoma and dysplasia in patients with jejuno-ileal Crohn's disease: prospective study in a cohort of high risk patients (DYDJI Study)
M. Simon*1, J. Cosnes2, P. Seksik3, M. Allez4, C. Stefanescu5, A. Blain6, M. Nachury7, S. Nancey8, L. Vuitton9, G. D'Haens10, J. Filippi11, S. Chevret12, D. Laharie13
1Institut Mutualiste Montsouris, Gastroenterology, Paris, France, 2Hopital Saint Antoine, Gastroenterology , Paris, France, 3Hopital Saint Antoine , Gastroenterology , Paris, France, 4Hopital Saint Louis, Gastroenterology , Paris, France, 5Hopital Beaujon, Gastroenterology Unit, Clichy, France, 6Institut Mutualiste Montsouris, Gastroenterology , Paris, France, 7Huriez Hospital, Gastroenterology, Lille, France, 8Hopital Lyon Sud - APHL, Gastroenterology, Pierre-Benite, France, 9CHU de Besancon, Gastroenterology, Besancon, France, 10Academic Medical Center, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 11CHU de Nice, Gastroenterology, Nice, France, 12Hopital Saint Louis, SBIM, Paris, France, 13CHU de Bordeaux, Gastroenterology, Pessac, France
Management and course of inflammatory bowel disease patients with associated cancer
I. Guerra1, A. Algaba1, E. Quintanilla2, J.L. Pérez-Calle3, M.C. García-Sánchez4, C. Taxonera5, G.J. Gómez6, M. Chaparro7, B. Botella8, R. Pajares9, M.D. Martín-Arranz10, Á. Castaño11, M. Arias2, A. López-Sanromán4, F. Bermejo1, 1Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain, 2Hospital Universitario Severo Ochoa, Gastroenterology, Madrid, Spain, 3Hospital Universitario Fundación Alcorcón, Gastroenterology, Madrid, Spain, 4Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 5Hospital Clinico San Carlos, Gastroenterology, Madrid, Spain, 6Hospital Doce de Octubre, Gastroenterology Unit, Madrid, Spain, 7Hospital Universitario La Princesa, Gastroenterology, Madrid, Spain, 8Hospital Universitario Infanta Cristina, Gastroenterology, Madrid, Spain, 9Hospital Universitario Infanta Sofía, Gastroenteology, Madrid, Spain, 10Hospital Universitario La Paz, Gastroenterology, Madrid, Spain, 11Hospital Universitario de Fuenlabrada, Pathology, Madrid, Spain
Differentiating neoplastic and non neoplastic raised lesions (polyps and pseudopolyps) in long-standing ulcerative colitis: Results from a prospective systematic study using virtual chromoendoscopy with FICE and the Kudo classification.
A. Cassinotti*1, F. Buffoli2, P. Fociani3, V. Villanacci4, T. Staiano2, M. Nebuloni3, M. Fichera1, R. Grassia2, G. Manes1, M. Salemme4, M. Lombardini1, P. Molteni1, G. Sampietro5, F. Furfaro1, A. Dell'Era1, P. Gambitta6, D. Foschi5, P. Duca7, R. de Franchis1, G. Maconi1, S. Ardizzone1
Table 2:
Table 1:
1Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy, 2Istituti Ospitalieri Cremona, Endoscopy Unit, Cremona, Italy, 3Luigi Sacco University Hospital, Pathology Unit, Milan, Italy, 4Spedali Civili, Pathology Unit, Brescia, Italy, 5Luigi Sacco University Hospital, General Surgery, Milan, Italy, 6Luigi Sacco University Hospital, Endoscopy Unit, Milan, Italy, 7Luigi Sacco University Hospital, Chair of Statistics, Milan, Italy
Efficacy of induction treatment with vedolizumab for patients with Crohn's disease who have experienced tumour necrosis factor antagonist failure or are tumour necrosis factor antagonist naive
W.J. Sandborn1, P. Rutgeerts2, J. Xu3, B. Abhyankar4, I. Fox5, 1University of California San Diego, Division of Gastroenterology, La Jolla, United States, 2Katholieke Universiteit and University Hospital Gasthuisberg, Division of Gastroenterology, Leuven, Belgium, 3Takeda Pharmaceuticals International Company, Biostatistics, Cambridge, United States, 4Takeda Development Centre (Europe) Ltd, Clinical Science, London, United Kingdom, 5Takeda Pharmaceuticals International Company, Clinical Development, Cambridge, United States
Regularities of expression of membrane-associated and cytoplasmic pattern recognition receptors, as well as transcriptional regulation of T-helper cells by lymphocytes in experimental ileitis and conduct of the simvastatin and aril-1
Z. Aleksandr*, K. Aleksandr
Zaporozhye State Medical University, Microbiology, Virology, and Immunology , Zaporozhye, Ukraine